Author: Jianghong An; Xuejiao Liao; Tongyang Xiao; Shen Qian; Jing Yuan; Haocheng Ye; Furong Qi; Chengguang Shen; Yang Liu; Lifei Wang; Xiaoya Cheng; Na Li; Qingxian Cai; Fang Wang; Jun Chen; Yingxia Liu; Yunfang Wang; Feng Zhang; Yang Fu; Xiaohua Tan; Lei Liu; Zheng Zhang
Title: Clinical characteristics of the recovered COVID-19 patients with re-detectable positive RNA test Document date: 2020_3_30
ID: 58sc6xgq_43
Snippet: The present study indicated RNA negative-conversion occurred commonly 2-3 weeks since the onset of illness in moderate RP patients as compared to more than 3 weeks in moderate NRP patients. The significantly shortened RNA negative-conversion time may affect the persistence of high levels of adaptive immunity [16] . Our recent studies indicated that a higher titer of antibody in the plasma was independently associated with disease severity in pati.....
Document: The present study indicated RNA negative-conversion occurred commonly 2-3 weeks since the onset of illness in moderate RP patients as compared to more than 3 weeks in moderate NRP patients. The significantly shortened RNA negative-conversion time may affect the persistence of high levels of adaptive immunity [16] . Our recent studies indicated that a higher titer of antibody in the plasma was independently associated with disease severity in patients with COVID-19 [17] . However, RP and NRP patients displayed similar levels of IgG and IgM in the plasma. Future study should investigate host immune responses which were usually considered to determine the clinical outcome especially in virus infection [18, 19] .
Search related documents:
Co phrase search for related documents- adaptive immunity and disease severity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- adaptive immunity and future study: 1
- adaptive immunity and high level: 1, 2, 3, 4, 5
- adaptive immunity and high titer: 1
- adaptive immunity and immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- adaptive immunity and negative conversion: 1
- adaptive immunity and present study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- antibody high titer and disease severity: 1, 2
- antibody high titer and high level: 1, 2, 3, 4, 5
- antibody high titer and high titer: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- antibody high titer and immune response: 1, 2, 3, 4, 5, 6, 7, 8
- antibody high titer and plasma antibody high titer: 1, 2, 3, 4, 5, 6
- clinical outcome and disease severity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- clinical outcome and future study: 1, 2, 3, 4, 5
- clinical outcome and high level: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- clinical outcome and high titer: 1, 2, 3
- clinical outcome and immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- clinical outcome and negative conversion: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- clinical outcome and negative conversion time: 1, 2
Co phrase search for related documents, hyperlinks ordered by date